Brief: EQRx Presents Phase 3 Data Of Lung Cancer Treatment At ESMO Congress
17/09/2021 12:07
Sept 17 (Reuters) - CM Life Sciences III Inc CMLT.O :
* EQRX ANNOUNCES PRESENTATION OF PHASE 3 DATA DEMONSTRATING
A
PROGRESSION-FREE SURVIVAL BENEFIT WITH SUGEMALIMAB CONSOLIDATION
THERAPY IN PATIENTS WITH STAGE III NSCLC AT ESMO CONGRESS 2021
Source text for Eikon: ID:nBw8yZ6RXa
Further company coverage: CMLT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on EQRx
See all newsBrief: Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Revolution Medicines Stockholders Vote "FOR" Proposed Acquisition Of EQRx, Inc
Brief: Revolution Medicines Inc Says Will Acquire EQRx In An All-Stock Transaction
U.S. RESEARCH ROUNDUP- Cigna Group, McKesson, Zscaler
Brief: EQRx posts Q1 EPS USD -0.17
Brief: EQRx Says Jami Rubin Will Step Down As Chief Financial Officer